PMID- 28315374
OWN - NLM
STAT- MEDLINE
DCOM- 20180307
LR  - 20180322
IS  - 1872-7549 (Electronic)
IS  - 0166-4328 (Linking)
VI  - 326
DP  - 2017 May 30
TI  - GLP-1 analogue CJC-1131 prevents amyloid beta protein-induced impirments of spatial 
      memory and synaptic plasticity in rats.
PG  - 237-243
LID - S0166-4328(16)31123-8 [pii]
LID - 10.1016/j.bbr.2017.03.018 [doi]
AB  - Although amyloid beta protein (Abeta) has been recognized as one of the main 
      pathological characteristics in the brain of Alzheimer's disease (AD), the 
      effective strategies against Abeta neurotoxicity are still deficient up to now. 
      Glucagon-like peptide 1 (GLP-1), a natural gut hormone, was found to be effective 
      in modulating insulin signaling and neural protection, but short half-life 
      limited its clinical application in AD treatment. CJC-1131, a newly designed 
      GLP-1 analogue with very longer half-life, has shown good effectiveness in the 
      treatment of type 2 diabetes mellitus (T2DM). However, it is unclear whether 
      CJC-1131 could alleviate Abeta-induced neurotoxicity in cognitive behavior and 
      electrophysiological property. The present study investigated the effects of 
      CJC-1131 on the Abeta-induced impairments in spatial memory and synaptic plasticity 
      of rats by using Morris water maze test and in vivo field potential recording. 
      The results showed that Abeta1-42-induced increase in the escape latency of rats in 
      hidden platform test and decrease in swimming time percent in target quadrant 
      were effectively reversed by CJC-1131 pretreatment. Further, CJC-1131 prevented 
      against Abeta1-42-induced suppression of hippocampal long term potentiation (LTP). 
      In addition, Abeta1-42 injection resulted in a significant decrease of p-PKA in the 
      hippocampus, which was effectively prevented by CJC-1131 treatment. These results 
      indicated that CJC-1131 protected the cognitive function and synaptic plasticity 
      of rats against Abeta-induced impairments, suggesting that GLP-1 analogue CJC-1131 
      might be potentially beneficial to the prevention and treatment of AD, especially 
      those with T2DM or blood glucose abnormality.
CI  - Copyright (c) 2017 Elsevier B.V. All rights reserved.
FAU - Zhang, Sheng-Xiao
AU  - Zhang SX
AD  - Department of Rheumatology, The Second Hospital of Shanxi Medical University, 56 
      Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Cai, Hong-Yan
AU  - Cai HY
AD  - Department of Microbiology and Immunology, Shanxi Medical University, 56 Xinjian 
      South Road, Taiyuan, Shanxi 030001, China.
FAU - Ma, Xiao-Wen
AU  - Ma XW
AD  - Department of Rheumatology, The Second Hospital of Shanxi Medical University, 56 
      Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Yuan, Li
AU  - Yuan L
AD  - Department of Physiology and National Key Discipline of Physiology, Shanxi 
      Medical University, 56 Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Zhang, Jun
AU  - Zhang J
AD  - Department of Physiology and National Key Discipline of Physiology, Shanxi 
      Medical University, 56 Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Wang, Zhao-Jun
AU  - Wang ZJ
AD  - Department of Physiology and National Key Discipline of Physiology, Shanxi 
      Medical University, 56 Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Li, Yu-Feng
AU  - Li YF
AD  - Department of Rheumatology, The Second Hospital of Shanxi Medical University, 56 
      Xinjian South Road, Taiyuan, Shanxi 030001, China.
FAU - Qi, Jin-Shun
AU  - Qi JS
AD  - Department of Physiology and National Key Discipline of Physiology, Shanxi 
      Medical University, 56 Xinjian South Road, Taiyuan, Shanxi 030001, China. 
      Electronic address: jinshunqi2009@163.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20170315
PL  - Netherlands
TA  - Behav Brain Res
JT  - Behavioural brain research
JID - 8004872
RN  - 0 (Amyloid beta-Peptides)
RN  - 0 (CJC 1131)
RN  - 0 (Maleimides)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Peptides)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
SB  - IM
MH  - Amyloid beta-Peptides/*adverse effects
MH  - Animals
MH  - Electrophysiological Phenomena
MH  - Glucagon-Like Peptide 1/*analysis
MH  - Hippocampus/*drug effects/physiopathology
MH  - Long-Term Potentiation/*drug effects
MH  - Male
MH  - Maleimides/administration & dosage/*pharmacology
MH  - Memory Disorders/chemically induced/*prevention & control
MH  - Neuronal Plasticity/*drug effects
MH  - Neuroprotective Agents/administration & dosage/*pharmacology
MH  - Peptides/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Spatial Memory/*drug effects
OTO - NOTNLM
OT  - Amyloid beta protein
OT  - CJC-1131
OT  - Long-term potentiation
OT  - Morris water maze
OT  - Spatial memory
OT  - Synaptic plasticity
EDAT- 2017/03/21 06:00
MHDA- 2018/03/08 06:00
CRDT- 2017/03/19 06:00
PHST- 2016/11/21 00:00 [received]
PHST- 2017/03/04 00:00 [revised]
PHST- 2017/03/08 00:00 [accepted]
PHST- 2017/03/21 06:00 [pubmed]
PHST- 2018/03/08 06:00 [medline]
PHST- 2017/03/19 06:00 [entrez]
AID - S0166-4328(16)31123-8 [pii]
AID - 10.1016/j.bbr.2017.03.018 [doi]
PST - ppublish
SO  - Behav Brain Res. 2017 May 30;326:237-243. doi: 10.1016/j.bbr.2017.03.018. Epub 
      2017 Mar 15.